Navigation Links
CSHL team develops mouse models of leukemia that predict response to chemotherapy
Date:3/31/2009

trolled by the p53 gene, a linchpin of the cell's anti-tumor defense response, as the key determinant of AML's aggressiveness and response to therapy.

Most patients with AML receive the same standardized treatment an initial phase of intense chemotherapy followed by additional chemotherapy cycles or bone marrow transplantation. Yet only a quarter of patients are cured and most die within a few months. This diversity in treatment response is due to AML's genetic heterogeneity, meaning that the hundred or so mutations associated with this form of cancer occur in different combinations in each patient and influence therapeutic outcomes in different ways.

Some gene mutations in cancer have been correlated with clinical outcome. But AML has proved to be genetically too complex, and the current experimental systems for predicting treatment response too unreliable for the information to be used in a standard way in the clinic.

These standard systems, in which anticancer drugs were tested in human cancer-cell lines, do not factor in the effects of a real tumor's environment on its growth. At the same time, placing these cells into animals to create a so-called "xenotransplant" model has not been an effective solution, according to Johannes Zuber, M.D., a Clinical Fellow in the Lowe lab who played a key role in the research and is first author on the team's paper. The reason, explains Zuber, is that "the cells are so poorly defined at the genetic level and tend to defy analysis of the molecular factors that influence drug response."

Making mice with human-like AML

Lowe's group surmounted these problems by first identifying the most commonly occurring mutations in a group of 111 children with AML and then engineering these mutations into mice, which soon developed leukemia. Among the participating AML patients, the two most common mutations were observed to occur when chromosomes broke apart and reattached in new places
'/>"/>

Contact: Hema Bashyam
bashyam@cshl.edu
516-367-6822
Cold Spring Harbor Laboratory
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. MIT student develops new innovations to selectively kill cancer cells
2. When acute hepatitis develops into chronic hepatitis
3. Fujitsu Develops HDD Security Technology Based on Opal SSC Standards
4. MIT develops new way to fuse cells
5. Hypertension develops early, silently, in African-American men
6. Iowa State researcher develops new treatment method for canine eye diseases
7. Lighting research center develops framework for assessing light pollution
8. AgriLife Research breeder develops drought-tolerant corn
9. Cocaine: How addiction develops
10. UCF professor develops vaccine to protect against black plague bioterror attack
11. Consortium develops new method enabling routine targeted gene modification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button Synaptics ... http://photos.prnewswire.com/prnh/20130307/600769 ... iPhone 5S, Samsung introduces for the first time a ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology used for ... overall facial feature of a person such as nose, ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... a powerful new method to investigate the discrete steps necessary ... goes wrong in cancer and other diseases. The finding, based ... 9 issue of Molecular Cell , allows scientists to ... activation. "The new methodology allows us to examine ...
... considered important habitats for marine life, but until recently, ... Researchers from Hawaii Pacific University (HPU) and the Universtiy ... the first extensive study of canyons in the oceanic ... especially abundant and unique communities of megafauna (large animals ...
... Reserve University School of Dental Medicine and School of ... human beta defensin peptide functionproteins important to the peripheral ... environment. They will examine brain tissues to explore ... brain diseases and in particular Alzheimer,s disease (AD). ...
Cached Biology News:Powerful new method allows scientists to probe gene activation 2Hawaiian submarine canyons are hotspots of biodiversity and biomass for seafloor animal communities 2Hawaiian submarine canyons are hotspots of biodiversity and biomass for seafloor animal communities 3Hawaiian submarine canyons are hotspots of biodiversity and biomass for seafloor animal communities 4Searching for brain's defenses to ward off infections, prevent memory loss 2
(Date:1/22/2015)... Boston, MA (PRWEB) January 22, 2015 ... systems, is pleased to announce an exciting product from a ... of motion analysis solutions over the past 15 years, with ... industries. Most recently, their 3D IMU system (inertial measurement unit), ...
(Date:1/22/2015)... Diagenode, Inc., a leading global provider ... complete solutions for epigenetics research, recently launched a ... need for manual processing. The new ChIPettor System ... histones or transcription factors and a semi-automated pipette ...
(Date:1/22/2015)... Jan. 22, 2015   GenoSpace , a precision medicine software ... enable the broad use of genomic, imaging and other biomedical ... of Michelle Munson , CEO of Aspera, an IBM ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We are ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... - Nearly 40% of Drugs on the Market and 30% of ... ... GPCRs -, HOPKINTON, Mass., May 5 Caliper ... Corporation that enables functional cell-based G protein-coupled,receptor (GPCR) assays from DiscoveRx ...
... Corporation of North,America today announces the immediate appointment ... her new role, Ms. Schwalm will have full,operating ... of Eisai Co., Ltd., Ms. Schwalm brings ... building,high-performing organizations that drive global growth and nearly ...
... CALGARY, May 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, ... Special Meeting,of the Shareholders will be held on Wednesday, ... Club of New York City, 50 Vanderbilt Ave, New ... Dr. Brad Thompson,President and CEO of Oncolytics, will discuss ...
Cached Biology Technology:Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization 2Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization 3Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc. 2Oncolytics Biotech Inc. Announces Details of 2008 Annual Shareholder Meeting 2
...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The 10-user network license entitles ten users to access data f...
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
Biology Products: